Does Gemtesa Have Anticholinergic Side Effects?
No, Gemtesa (vibegron) does not have anticholinergic side effects—it is a β3-adrenergic receptor agonist with a completely different mechanism of action from anticholinergic medications.
Mechanism of Action
Vibegron works by stimulating β3-adrenergic receptors in the bladder detrusor muscle, causing relaxation and increased bladder capacity 1. This is fundamentally different from anticholinergic agents (like oxybutynin, tolterodine, or solifenacin), which block muscarinic receptors to reduce bladder contractions 2.
Why This Distinction Matters Clinically
The absence of anticholinergic activity is a major clinical advantage, particularly for:
Older adults: Anticholinergic medications cause cognitive impairment, increased fall risk, constipation, dry mouth, urinary retention, and blurred vision through broad muscarinic receptor blockade 2. These effects are poorly tolerated in elderly patients and contribute to "anticholinergic burden," which is associated with decline in cognition, functional status, and activities of daily living 2.
Patients on polypharmacy: Vibegron has minimal drug interactions and does not interact with cytochrome P450 enzymes, unlike some other OAB medications 3. This makes it safer in patients taking multiple medications.
Cardiovascular safety: Dedicated ambulatory blood pressure monitoring studies confirm vibegron has no clinically meaningful effects on blood pressure or heart rate 4.
Side Effect Profile
The FDA label 1 lists the most common adverse reactions as:
- Urinary tract infection
- Headache
- Nasopharyngitis
- Diarrhea
- Nausea
- Upper respiratory tract infection
Notably absent: dry mouth, constipation, cognitive impairment, and blurred vision—the hallmark anticholinergic side effects 4, 3.
Clinical Evidence
Multiple studies confirm vibegron's favorable tolerability profile compared to anticholinergics. In the pivotal EMPOWUR trial, drug-related adverse events with vibegron (5.4-7.6%) were similar to placebo (5.1%) and lower than the anticholinergic comparator imidafenacin (10.3%) 5. Long-term data over 52 weeks demonstrates sustained safety 4, 6.
Key Clinical Pitfall to Avoid
Do not confuse vibegron with anticholinergics when counseling patients. While both treat overactive bladder, vibegron should be specifically highlighted as not having anticholinergic effects, making it particularly appropriate for:
- Elderly patients at risk for cognitive decline
- Patients with constipation or dry mouth concerns
- Those who failed anticholinergics due to side effects
- Patients with high anticholinergic burden from other medications 7
The guideline evidence emphasizes that strongly anticholinergic overactive bladder agents like oxybutynin should be deprescribed in older adults due to their adverse effects on cognition and function 2. Vibegron represents a non-anticholinergic alternative that avoids this entire class of side effects 8, 4, 3.